Morphine or Oxycodone in Cancer Pain?

References

• Levy MH. Pharmacological treatment of cancer pain. N Engl J Med 1996; 335: 1124–32.
   PubMed Web of Science ®Google Scholar
• de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10: 378–84.
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Zecca E, Bruera E An update on the clinical use of methadone for cancer pain. Pain 1997; 70: 109–15.
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Kalso E Controlled-release oxycodone and morphine in cancer related pain. Pain 1997; 73: 37–45.
   PubMed Web of Science ®Google Scholar
• Kalso E, Poyhiä R, Onnela P, Linko K, Tigerstedt I, Tam-misto T. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 1991; 35: 642–6.
   PubMed Web of Science ®Google Scholar
• Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47: 639–46.
   PubMed Web of Science ®Google Scholar
• Otton SW, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibi-tion by iluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401–9.
   Google Scholar
• Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17: 102–5.
   Google Scholar
• Kaiko R, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD. Pharmacokinetic-pharmacodynamic rela-tionships of controlled-release oxycodone. Clin Pharmacol Ther 1996; 59: 52–61.
   PubMed Web of Science ®Google Scholar
• Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Cau-casians: frequency of a new oxidative drug metabolism poly-morphism. Clin Pharmacol Ther 1984; 36: 773–80.
   Google Scholar
• Weinstein SC, Gaylord JC. Determination of oxycodone in plasma and identification of a major metabolite. J Pharmacol Sci 1979; 68: 527–8.
   PubMed Web of Science ®Google Scholar
• Pöyhiä R, Seppäld T, Olkkola KT, Kalso E The pharmacoki-netics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992; 33: 617–21.
   PubMed Web of Science ®Google Scholar
• Svensson JO. Determination of morphine, morphine-6-glu-curonide and normorphine in plasma and urine with high performance liquid electrochemical detection. J Chromatogr 1986; 375: 174–8.
   Web of Science ®Google Scholar
• Hanks GW, Twycross RG, Bliss JM. Controlled-release mor-phine tablets: a double-blind trial in patients with advanced cancer. Anaesthesia 1987; 42: 840–4.
   Google Scholar
• McQuay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, Moore RA. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990; 48: 236–44.
   PubMed Web of Science ®Google Scholar
• Faura CC, Collins SL, Moore RA, McQuay HJ. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 1998; 74: 43–53.
   PubMed Web of Science ®Google Scholar
• Neumann PB, Henriksen H, Christensen CB. Plasma mor-phine concentrations during chronic oral administration in patients with cancer pain. Pain 1982; 13: 247–52.
   Google Scholar
• Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient vari-ability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 1996; 60: 601–7.
   Google Scholar
• Wolff T, Samuelsson H, Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine adminis-tration. Pain 1995; 62: 147–54.
   Google Scholar
• Vater M, Smith G, Aherne GW, Aitkenhead AR. Pharmacoki-netics and analgesic effect of slow-release oral morphine sulphate in volunteers. Br J Anaesth 1984; 58: 821–7.
   Google Scholar
• Drake J, Kirkpatrick CT, Aliyar CA, Crawford FE, Gibson P, Horth CE. Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulations: oramorph SR and MST continus. Br J Clin Pharmacol 1996; 41: 417–20.
   PubMed Web of Science ®Google Scholar
• Leow KP, Smith MT, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxy-codone in patients with cancer. ain Pharmacol Ther 1992; 52: 487–95.
   Google Scholar
• Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different route of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990; 47: 12 — 9.
   PubMedGoogle Scholar
• Beaver WT, Wallenstein SL, Rogers A, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer II: comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Pharmacol Exp Ther 1978; 207: 101–8.
   PubMed Web of Science ®Google Scholar
• Tallgren M, Olkkola KT, Seppäld T, H6ckerstedt K, Lindgren L. Pharmacokinetics of oxycodone before and after liver transplantation. Clin Pharmacol Ther 1997; 61: 655–61.
   Google Scholar
• Kotb HIM, El-Kabsh MY, Emara SES, Fouad EA. Pharma-cokinetics of controlled release morphine (MST) in patients with liver cirrhosis. Br J Anaesth 1997; 79: 804–6.
   PubMedGoogle Scholar
• Kirveld M, Lindgren L, Seppälä T, Olkkola KT. The pharma-cokinetics of oxycodone in uremic patients undergoing renal transplantation. J ain Anesth 1996; 8: 13–8.
   Google Scholar
• Osborne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. ain Pharmacol Ther 1993; 54: 158–67.
   Google Scholar